Here’s the story in Forbes:
“What if a simple blood test could detect any cancer early, when it was still easy to treat?
It sounds like science fiction. But Illumina ILMN -0.61%, the $24 billion (market cap) biotechnology company that has pioneered cheap, efficient sequencing of DNA, says it could be a reality in a few years. It is launching a new startup, GRAIL (because such a test would be a holy grail for cancer doctors), with $100 million in funding.”
“Wyss-Coray formed a start-up company, Alkahest in Menlo Park, California, and in September 2014 it began a randomized, placebo-controlled, double-blind trial at Stanford, testing the safety and efficacy of using young plasma to treat Alzheimer’s disease. Six out of a planned 18 people with Alzheimer’s, all aged 50 or above, have already begun to receive plasma harvested from men aged 30 or younger. In addition to monitoring disease symptoms, the researchers are looking for changes in brain scans and blood biomarkers of the disease.”
And from Stanford Medicine:
“Something — or some things — in the blood of young mice has the ability to restore mental capabilities in old mice, a new study by Stanford University School of Medicine investigators has found.
If the same goes for humans, it could spell a new paradigm for recharging our aging brains, and it might mean new therapeutic approaches for treating dementias such as Alzheimer’s disease.”
It’s still a long way away, but this is a great idea (and from Singularity University).
“A new startup, dubbed Miroculus, is building a device that could easily and affordably check for dozens of cancers using a single blood sample. Known as Miriam, this low-cost, open source device made its public debut at the TEDGlobal conference in Rio De Janeiro on Thursday, with TED curator Chris Anderson calling it “one of the most thrilling demos in TED history.”
Here’s a piece I wrote for Slate.
“Silicon Valley, known for entrepreneurs, gadget lovers, and paradigm breakers, has recently turned its attention towards longevity, powering an important cultural change on the topic. The interests of these movers and shakers run the gamut, from using technology to improve our clunky healthcare system to literally solving the problem of aging.”
Read more here.
The Financial Times posted an interesting article about Craig Venter and his new longevity company, Human Longevity Inc. When the journalist asks him if his company is in competition with Google’s Calico (also set up to extend human healthspan), Venter says this:
“I turn 68 later this year and if they solve ageing before we do, I will kiss the rings and buy their products.”
Couldn’t agree more.